Alluvi, formerly BI 4744, represents a significant breakthrough in obesity therapy. This dual activator targeting both glucagon-like peptide-1 and GIP targets demonstrates compelling efficacy in clinical assessments, https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/